Kyowa Kirin (KYKO.F) Stock Overview
Engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 5/6 |
KYKO.F Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Join community and earn perks
Kyowa Kirin Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥15.80 |
| 52 Week High | JP¥18.00 |
| 52 Week Low | JP¥12.42 |
| Beta | 0.14 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -12.08% |
| 5 Year Change | -56.41% |
| Change since IPO | 192.57% |
Recent News & Updates
Recent updates
Shareholder Returns
| KYKO.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -3.4% | -1.0% |
| 1Y | n/a | 44.7% | 14.1% |
Return vs Industry: Insufficient data to determine how KYKO.F performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how KYKO.F performed against the US Market.
Price Volatility
| KYKO.F volatility | |
|---|---|
| KYKO.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 8.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: KYKO.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine KYKO.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1949 | 5,161 | Abdul Hafeez Mullick | www.kyowakirin.com |
Kyowa Kirin Co., Ltd. engages in the research, development, manufacturing, and marketing of pharmaceuticals in Japan, the Americas, Europe, Asia, and internationally. The company offers Ziftomenib, an oral menin inhibitor for the treatment of adult relapsed or refractory and acute myeloid leukemia with a nucelophosmin1 mutation; and Lumicef for the treatment of palmoplantar pustulosis. It also develops KHK4083/AMG 451 rocatinlimab, which is in Phase III clinical trial for the treatment of moderate to severe atopic dermatitis and prurigo nodularis; KK8398 infigratinib, which is in Phase III clinical trial for the treatment of achondroplasia; OTL-203, which is in Phase III clinical trial for the treatment of hurler syndrome; KHK4951 tivozanib, which is in Phase II clinical trial for the treatment of diabetic macular edema and neovascular age-related macular degeneration; and OTL-201, which is in Phase II clinical trial for the treatment of sanfilippo syndrome type A. In addition, the company is involved in the development of KK2260 and KK2269, which are both in Phase I clinical trials for the treatment of advanced or metastatic solid tumors; KK2845, which is in Phase I clinical trial for the treatment of acute myeloid leukemia; KK3910, which is in Phase I clinical trial for the treatment of essential hypertension; KK4277, which is in Phase I clinical trial for the treatment of systemic/cutaneous lupus erythematosus; and KK8123, which is in Phase I clinical trial for the treatment of X-linked hypophosphatemia.
Kyowa Kirin Co., Ltd. Fundamentals Summary
| KYKO.F fundamental statistics | |
|---|---|
| Market cap | US$7.47b |
| Earnings (TTM) | US$529.23m |
| Revenue (TTM) | US$3.45b |
Is KYKO.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KYKO.F income statement (TTM) | |
|---|---|
| Revenue | JP¥529.80b |
| Cost of Revenue | JP¥132.42b |
| Gross Profit | JP¥397.38b |
| Other Expenses | JP¥316.04b |
| Earnings | JP¥81.34b |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
Nov 02, 2026
| Earnings per share (EPS) | 155.35 |
| Gross Margin | 75.01% |
| Net Profit Margin | 15.35% |
| Debt/Equity Ratio | 0% |
How did KYKO.F perform over the long term?
See historical performance and comparisonDividends
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/12 21:58 |
| End of Day Share Price | 2026/09/02 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Kyowa Kirin Co., Ltd. is covered by 18 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |